Loading stock data…
JAZZ
$223.44-2.35 (-1.04%)
Market OpenUpdated 3:59 PM EDT
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jazz Pharmaceuticals plc in the Healthcare sector is trading at $223.52. The stock is currently near its 52-week high of $230.40, remaining 40.1% above its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why JAZZ maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$223.44
Potential Upside
5%
Whystock Fair Value$234.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$241.76+8.2%
Range$188.00 – $281.00
Fundamentals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.37%
Volume
Today's trading volume
816,400
Recent News
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Is It Time To Reevaluate Jazz Pharmaceuticals (JAZZ) After A 125% One Year Rally?
If you are wondering whether Jazz Pharmaceuticals at US$228.57 still offers value after a strong run, the next sections will help you put the current share price into context. The stock has posted returns of 14.3% over the last 7 days, 22.3% over 30 days, 32.0% year to date and 125.3% over 1 year. This puts recent price action front and center for any valuation discussion. Recent attention on Jazz Pharmaceuticals has focused on its position within the broader pharmaceuticals and biotech...
Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC Says
Jazz Pharmaceuticals (JAZZ) delivered a "strong" Q1 as broad-based growth across its commercial port
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.
Jazz Pharmaceuticals plc Q1 2026 Earnings Call Summary
Moby summary of Jazz Pharmaceuticals plc's Q1 2026 earnings call